Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Trial Details

NCT ID

NCT06348134

Phase

PHASE2

Sponsor

University of Chicago

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Trastuzumab emtansine
Pertuzumab Injection
Docetaxel
Tamoxifen
Letrozole
Goserelin

Locations (sample)

Ikeja, Lagos, Nigeria|6.59651,3.34205
Yaba, Lagos, Nigeria|6.51395,3.37389
Ile-Ife, Osun State, Nigeria|7.4824,4.56032
Ibadan, Oyo State, Nigeria|7.37756,3.90591

Key Eligibility Criteria

Written informed consent must be obtained prior to any screening procedures
Women ages of 18 to 70 years old
Biopsy-accessible breast tumor of significant size for core needle biopsy /ultrasound measurable (≥ 2cm)
Measurable breast tumour using ultrasonography (≥ 2cm)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →